CRO Services for Colorectal Cancer Clinical Trials

Colorectal cancer (CRC) remains one of the most clinically active areas of oncology drug development. Sponsors advancing therapies in CRC face a specific set of operational challenges: heterogeneous patient populations across MSI-H and MSS subtypes, complex eligibility criteria that require biomarker screening at enrollment, and the increasing use of combination regimens that demand careful safety monitoring and supply management.

Sitero has direct experience supporting colorectal cancer clinical trials, and our model addresses the operational demands of CRC development from startup through closeout.

Patient Recruitment in CRC Trials

Enrollment in colorectal cancer studies is rarely straightforward. Biomarker-driven eligibility — such as MSI-H or RAS/RAF mutation status — reduces the eligible population significantly and requires tight coordination between the sponsor, investigative sites, and central laboratories. Sitero works with oncology-focused clinical sites and academic centers with established CRC patient populations. We support targeted site selection based on patient access, coordinate with central labs for biomarker screening, and maintain active site engagement to minimize screening failure rates and protect enrollment timelines.

Safety Monitoring for CRC Combination Regimens

Colorectal cancer trials increasingly involve combinations — immunotherapy plus chemotherapy, or targeted agents combined with standard-of-care backbones. These regimens carry complex safety profiles that require continuous pharmacovigilance oversight. Sitero’s drug safety team manages end-to-end case processing, aggregate reporting, and signal detection with regulatory readiness as the baseline expectation.

Data Management for CRC Endpoints

CRC trials frequently involve response assessments, biomarker data, and patient-reported outcomes alongside standard clinical data. Sitero’s EDC and biometrics capabilities are configured for complex oncology endpoints, supporting clean, analysis-ready data at closeout — where sponsors on the Mentor platform have seen a 60% decrease in data management closeout timelines.

Reducing Site Burden

Investigator sites running CRC trials are managing high patient acuity alongside complex protocol requirements. Sitero’s integrated eConsent, EDC, and RTSM platform reduces the manual coordination burden on sites, contributing to a 54% decrease in administrative costs at the site level across our oncology programs.

Integrated Oversight Across the Trial

Sponsors managing colorectal cancer programs benefit from Sitero’s integrated model — where clinical operations, safety, data management, and technology work under one operational framework. This reduces the coordination overhead between functions that typically slows CRC programs down, and gives sponsor teams a single point of accountability from startup through closeout.